|
|
News Breaks | | | | January 31, 2013 | | 07:43 EDT |  | AMRN | Amarin receives two new patent allowances related to Vascepa
Amarin announced that the United States Patent and Trademark Office, or USPTO, has published notification of Notices of Allowance for Amarin's U.S. Patent Applications Serial Numbers 13/458,496 and 13/349,157. The allowed '496 and '157 applications continue to broaden our claimed methods of reducing triglycerides consistent with the FDA approved MARINE indication for Vascepa capsules through use of a pharmaceutical composition of highly pure icosapent ethyl, or EPA. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patents would have terms that expire no earlier than in 2030. After issuance, Amarin plans to list these patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. | |
|
News For AMRN From The Last 14 Days Check below for free stories on AMRN the last two weeks. |
|
|
| May 17, 2013 | | 14:12 EDT | | AMRN | Amarin shares slip after FDA updates Orange Book
 Subscribe for More Information | | | May 15, 2013 | | 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. | | | May 13, 2013 | | 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information | | | May 10, 2013 | | 09:23 EDT |  | AMRN | Amarin continues to make progress with payors, says Leerink
Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. | | | May 9, 2013 | | 16:18 EDT |  | AMRN | Amarin reports Q1 EPS (41c), consensus (39c)
Reports Q1 revenue $2.34M, consensus $5.2M. Amarin said its direct sales force, consisting of approximately 275 sales professionals, made sales calls to clinicians for two months in Q1. Amarin reports that, since launch, access to clinicians has been good, and that it has yet to hear any significant negative reaction to the efficacy or safety profile of Vascepa. Amarin said it continues to make significant progress in its effort to expand patent protection for Vascepa and now has 22 patents issued or allowed in the United States with over 30 additional U.S. patent applications being prosecuted. | | | 13:15 EDT | | AMRN | Amarin, Omthera drop following fatty acids study in journal
Subscribe for More Information | |
|
|
|
|
|
|
